BACKGROUND: A new method for detecting circulating Ewing sarcoma cells using flow cytometry is described. This strategy exploits the nearly universal expression of CD99 and the lack of expression of CD45 by Ewing sarcoma cells. PROCEDURE: Ewing sarcoma cell line A673, peripheral blood mononuclear cells (PBMCs), and bone marrow mononuclear cells (BMMCs) were stained for CD99 and CD45 in order to detect CD99+CD45- cells by flow cytometry. Known quantities of A673 Ewing sarcoma cells were spiked into control PBMCs to test the accuracy of this method. Control PBMCs were evaluated to assess the level of background staining. RESULTS: Flow cytometry was accurate at frequencies as low as one A673 cell per 500,000 PBMCs. The background rate of CD99+CD45- cell detection was low in PBMCs from nine healthy volunteers (median 0.0001% of total cells; range 0-0.00046%) and was further reduced by incorporating stains to exclude dead cells, progenitor cells, and monocytes. In one subject with newly diagnosed localized Ewing sarcoma, CD99+CD45- cells were detected in both blood (0.0021%) and bone marrow (0.048%). CONCLUSIONS: Multicolor flow cytometry for CD99+CD45- cells provides a new strategy for detecting circulating Ewing sarcoma cells. Clinical evaluation and validation of this method is ongoing. Copyright 2009 Wiley-Liss, Inc.
BACKGROUND: A new method for detecting circulating Ewing sarcoma cells using flow cytometry is described. This strategy exploits the nearly universal expression of CD99 and the lack of expression of CD45 by Ewing sarcoma cells. PROCEDURE: Ewing sarcoma cell line A673, peripheral blood mononuclear cells (PBMCs), and bone marrow mononuclear cells (BMMCs) were stained for CD99 and CD45 in order to detect CD99+CD45- cells by flow cytometry. Known quantities of A673 Ewing sarcoma cells were spiked into control PBMCs to test the accuracy of this method. Control PBMCs were evaluated to assess the level of background staining. RESULTS: Flow cytometry was accurate at frequencies as low as one A673 cell per 500,000 PBMCs. The background rate of CD99+CD45- cell detection was low in PBMCs from nine healthy volunteers (median 0.0001% of total cells; range 0-0.00046%) and was further reduced by incorporating stains to exclude dead cells, progenitor cells, and monocytes. In one subject with newly diagnosed localized Ewing sarcoma, CD99+CD45- cells were detected in both blood (0.0021%) and bone marrow (0.048%). CONCLUSIONS: Multicolor flow cytometry for CD99+CD45- cells provides a new strategy for detecting circulating Ewing sarcoma cells. Clinical evaluation and validation of this method is ongoing. Copyright 2009 Wiley-Liss, Inc.
Authors: Massimo Cristofanilli; Daniel F Hayes; G Thomas Budd; Mathew J Ellis; Alison Stopeck; James M Reuben; Gerald V Doyle; Jeri Matera; W Jeffrey Allard; M Craig Miller; Herbert A Fritsche; Gabriel N Hortobagyi; Leon W M M Terstappen Journal: J Clin Oncol Date: 2005-03-01 Impact factor: 44.544
Authors: A Zoubek; R Ladenstein; R Windhager; G Amann; G Fischmeister; L Kager; D Jugovic; P F Ambros; H Gadner; H Kovar Journal: Int J Cancer Date: 1998-02-20 Impact factor: 7.396
Authors: K Scotlandi; N Baldini; V Cerisano; M C Manara; S Benini; M Serra; P L Lollini; P Nanni; G Nicoletti; G Bernard; A Bernard; P Picci Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: Sunitha Nagrath; Lecia V Sequist; Shyamala Maheswaran; Daphne W Bell; Daniel Irimia; Lindsey Ulkus; Matthew R Smith; Eunice L Kwak; Subba Digumarthy; Alona Muzikansky; Paula Ryan; Ulysses J Balis; Ronald G Tompkins; Daniel A Haber; Mehmet Toner Journal: Nature Date: 2007-12-20 Impact factor: 49.962
Authors: I Yaniv; J Stein; D Luria; I J Cohen; E Liberzon; S Manor; A Grunshpan; Y Sverdlov; Y Kodman; J Issakov; M Feinmesser; R Zaizov; S Avigad Journal: Bone Marrow Transplant Date: 2007-03-19 Impact factor: 5.483
Authors: Neerav N Shukla; Juber A Patel; Heather Magnan; Ahmet Zehir; Daoqi You; Jiabin Tang; Fanli Meng; Aliaksandra Samoila; Emily K Slotkin; Srikanth R Ambati; Alexander J Chou; Leonard H Wexler; Paul A Meyers; Ellinor I Peerschke; Agnes Viale; Michael F Berger; Marc Ladanyi Journal: JCO Precis Oncol Date: 2017-05-23
Authors: Arun Satelli; Abhisek Mitra; Jeffry J Cutrera; Marcos Devarie; Xueqing Xia; Davis R Ingram; Denada Dibra; Neeta Somaiah; Keila E Torres; Vinod Ravi; Joseph A Ludwig; Eugenie S Kleinerman; Shulin Li Journal: Cancer Res Date: 2014-01-21 Impact factor: 12.701
Authors: Kieuhoa T Vo; Jeremy V Edwards; C Lorrie Epling; Elizabeth Sinclair; Douglas S Hawkins; Holcombe E Grier; Katherine A Janeway; Phillip Barnette; Elizabeth McIlvaine; Mark D Krailo; Donald A Barkauskas; Katherine K Matthay; Richard B Womer; Richard G Gorlick; Stephen L Lessnick; Crystal L Mackall; Steven G DuBois Journal: Clin Cancer Res Date: 2016-02-09 Impact factor: 12.531
Authors: Allison F O'Neill; Jason L J Dearling; Yuchuan Wang; Tanya Tupper; Yanping Sun; Jon C Aster; Monica L Calicchio; Antonio R Perez-Atayde; Alan B Packard; Andrew L Kung Journal: Clin Cancer Res Date: 2013-11-11 Impact factor: 12.531
Authors: Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick Journal: Mol Cell Biol Date: 2013-09-16 Impact factor: 4.272
Authors: Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167